GPT and cholestasis: In the pembrolizumab arm, grade ≥3 AEs were considered related to pembrolizumab in 18% of patients (two patients with anemia [with thrombocytopenia in one patient], one patient with diarrhea/dehydration/hypokalemia, one patient with ALT increased/AST increased/blood alkaline phosphatase increased/GGT increased, and one patient each with congestive cardiomyopathy, hypothyroidism, aptyalism, autoimmune hepatitis, cholestasis, cachexia, and acute kidney injury).